Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology

RJ Motzer, E Jonasch, N Agarwal, A Alva… - Journal of the National …, 2022 - jnccn.org
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging,
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …

Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study

A Sanchez, H Furberg, F Kuo, L Vuong, Y Ged… - The Lancet …, 2020 - thelancet.com
Background Obesity is associated with an increased risk of developing clear cell renal cell
carcinoma (RCC) but, paradoxically, obesity is also associated with improved oncological …

Novel emerging biomarkers to immunotherapy in kidney cancer

Y Ged, MH Voss - Therapeutic Advances in Medical …, 2021 - journals.sagepub.com
The treatment of metastatic renal cell carcinoma has significantly evolved in recent years,
particularly with the advent of novel immune checkpoint inhibitors (ICI). Despite the striking …

Metastatic chromophobe renal cell carcinoma: Presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes

Y Ged, YB Chen, A Knezevic, J Casuscelli… - Clinical genitourinary …, 2019 - Elsevier
Background Sarcomatoid features (SF) in renal cell carcinoma (RCC) denote poor
prognosis. Data for metastatic chromophobe RCC (ChRCC) with SF are limited. We studied …

Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma

Y Ged, CH Lee - Expert Review of Anticancer Therapy, 2022 - Taylor & Francis
Introduction The treatment landscape of metastatic renal cell carcinoma (RCC) has
significantly evolved in recent years with the advent and approval of multiple combinations …

[HTML][HTML] DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy

Y Ged, JL Chaim, RG DiNatale, A Knezevic… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Loss-of-function alterations in DNA damage repair (DDR) genes are associated
with human tumorigenesis and may determine benefit from immune-oncology (I/O) agents …

Comprehensive molecular characterization and response to therapy in fumarate hydratase–deficient renal cell carcinoma

JP Gleeson, I Nikolovski, R Dinatale, M Zucker… - Clinical Cancer …, 2021 - AACR
Purpose: Fumarate hydratase–deficient renal cell carcinoma (FH-RCC) is a rare, aggressive
form of RCC associated with hereditary leiomyomatosis and RCC syndrome. Evidence for …

[HTML][HTML] A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response

AA Hakimi, K Attalla, RG DiNatale, I Ostrovnaya… - Nature …, 2020 - nature.com
There is conflicting data regarding the role of PBAF complex mutations and response to
immune checkpoint blockade (ICB) therapy in clear cell renal cell carcinoma (ccRCC) and …

Associations between pretreatment body composition features and clinical outcomes among patients with metastatic clear cell renal cell carcinoma treated with …

Y Ged, A Sanchez, S Patil, A Knezevic, E Stein… - Clinical Cancer …, 2022 - AACR
Purpose: High body mass index (BMI) may lead to improved immune-checkpoint blockade
(ICB) outcomes in metastatic clear cell renal cell carcinoma (mccRCC). However, BMI is a …

The shifting treatment paradigm of metastatic renal cell carcinoma

Y Ged, MC Markowski, N Singla, SP Rowe - Nature Reviews Urology, 2022 - nature.com
The treatment landscape of renal cell carcinoma is rapidly evolving, especially with the
introduction and approval of immune checkpoint inhibitor combination therapies. Clinical …